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Available online 13 April 2014AbstractObjective: The purpose of the study was to synthesize potent acetylcholinesterase (AChE) inhibitor and cytotoxic compounds by condensing
acetazolamide with azetidinones.
Methods: A new series of novel acetazolamide condensed azetidinones was prepared by Schiff’s bases of acetazolamide with chloroacetyl-
chloride in the presence of a catalytic amount of 1,4-dioxane and triethyl amine. Confirmation of the chemical structure of the synthesized
compounds (5aek) was substantiated by melting point, thin layer chromatography, different spectral data infrared, 1H-nuclear magnetic
resonance, and mass spectra. The synthesized compounds were evaluated for AChE inhibitory activity and in vitro cytotoxicity against Vero
cells.
Results: The titled compounds exhibited weak, moderate, or high AChE inhibitory activity and in vitro cytotoxicity. Compound 5c exhibited
potential AChE inhibitory activity, with a concentration of 0.10mM giving 50% inhibition, when compared with the current therapeutic agent
donepezil HCl and in vitro cytotoxicity with a lower concentration required to kill 50% of the cells.
Conclusion: Acetazolamide-cyclocondensed azetidinones might prove interesting as potential AChE inhibitors and cytotoxic compounds, and
should be investigated further.
Copyright  2014, Taiwan Society of Emergency Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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The activity of famous antibiotic classes such as the peni-
cillins, cephalosporins, carumonam, aztreonam, thienamicine,
nocardicins, and carbapenems is attributed to the presence of a
2-azetidinone ring.1 Unfortunately, the most widely used of
them exert selective pressure on bacteria and permit the pro-
liferation of resistant organisms. Several synthetic and* New Drug Discovery Research, Department of Medicinal Chemistry,
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2211-5587/Copyright  2014, Taiwan Society of Emergency Medicine. Publishedsemisynthetic b-lactam antibiotics have been developed due to
the growing resistance of bacteria towards the classics b-lac-
tam antibiotics and the need for drugs with a more specific
antibacterial activity.2 The name lactam is given to cyclic
amides. In older nomenclature the second carbon in an
aliphatic carboxylic acid was designated as a, the third as b
and so on. Thus a b-lactam is a cyclic amide with four atoms
in its ring. The contemporary name for this ring system is
azetidinone although b-lactam has come to be a generic
descriptor for the penicillin family. The ring ultimately proved
to be the main component of the pharmacophore.3,4 Therefore,
the term possesses medicinal as well as chemical significance.
Keteneeimine cycloaddition was reported by Staudinger5 toby Elsevier Taiwan LLC. All rights reserved.
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substituted b-lactam derivatives. In an effort to investigate a
suitably substituted monocyclic b-lactam as a minimum
requirement for biological activity, many scientists reported
the trans-stereoselective synthesis of butadienyl azetidinones
and their DielseAlder cycloaddition.5,6 This included the
preparation of a series of Schiff’s bases and their reaction with
dienylketene to produce a transazetidinone. This involved the
in situ formation of the ketene and its subsequent addition to
the imine.7,8
The 2-azetidinone skeleton, otherwise known as the b-
lactam ring, has been recognized as a useful building block in
the synthesis of biologically important compounds. Azetindin-
2-one derivatives display interesting biological activities such
as antimicrobial,9e11 antitubercular,12,13 analgesic, anti-in-
flammatory,14 chymase inhibitory,15 antitumor,16,17 cholesterol
absorption inhibitory properties,18 antinociceptive,19 and
anticonvulsant.20 The chemical structure of acetazolamide
provides a most valuable molecular template for the devel-
opment of agents able to interact with a wide variety of bio-
logical activities. The synthesis of acetazolamide condensed
with azetidinones has not been reported previously. Hence, it
was thought worthwhile to synthesize new congeners by
incorporating acetazolamide and azetidinone moieties in a
single molecular framework and to evaluate their acetylcho-
linesterase (AChE) inhibitor activity and in vitro cytotoxicity.
2. Materials and methods
All chemicals were supplied by E. Merck (Merck Feld-
bergstr. 78, 64293 Darmstadt, Germany) and S.D. Fine
Chemicals (315e317, T V Industrial Estate, 248, Worli Road,
BDD Chawls Worli, Worli, Mumbai, Maharashtra 400018,
India). The melting points (MP) of the synthesized compounds
were determined in open capillaries using a Veego VMP-1
apparatus and are expressed in C and are uncorrected. The
IR spectra of compounds were recorded on Shimadzu FT-IR
spectrometer using the KBr pellet technique and are
expressed in cm1. 1H NMR spectra was recorded on Bruker
DRX-300 (300 MHz FT-NMR) using dimethyl sulfoxide
(DMSO)-d6 as solvent and tetramethylsilane as internal stan-
dard. The chemical shifts were reported in ppm. Mass spectra
MS were obtained using Shimadzu LCMS 2010A under ESI
ionization technique.2.1. Synthesis of Schiff’s bases (1aej)A mixture of equimolar quantities of compound acetazol-
amide (0.01M) and appropriate aryl and heteroaryl aldehyde
(0.01M) was dissolved in ethanol (95%). The contents were
relaxed for 3.5 hours on a steam bath. The solid obtained was
separated out and crystallized from ethanol. The synthesized
compounds yield ranges were found to be 62e78% and
melting point range was 152e208C. The infrared (IR) spectra
of compounds 1aej showed strong absorption bands for
carbonyl group (1720 cm1), aromatic CeH Stretching
(3186 cm1), and aromatic C]C Stretching (1630 and1520 cm1). 1H-nuclear magnetic resonance (NMR) spectra of
compounds 1aej showed a quartet for methine protons at 7.8
(1H, N]CHeR), multiplets at 6.2e7.8 (AreH). Compounds
1d and 1g showed a singlet at 2.24 due to the signals of the
third CH group.2.2. Synthesis of azetidinones (5aek)Triethylamine (0.01M) in 1,4-dioxane, chloroacetyl chlo-
ride (0.01M) was added drop wise to a solution of the com-
pounds 1a-k (0.005M) at room temperature. The reaction
mixture was stirred for 25 minutes and then refluxed for 4.5
hours on a water bath. The solid obtained after removal of 1,4-
dioxane was crystallized from ethanol. The yield, melting
point, and spectral characterization of the compounds were
reported in analytical data.2.3. Analytical data
2.3.1. N-{5-[(3-chloro-2-oxo-4-phenylazetidine1-yl)
sulfonyl]e1,3,4-thiadiazol-2-yl}acetamide (5a)
Colorless amorphous solid; MP: 218e220C; yield: 72%;
IR (KBr, cm1): 3310 (NeH), 3048 (ArCeH), 1678 (C]O,
amide), 1520 (ArC]C), 1380 (CeN), and 710 (CeCl); 1H-
NMR (DMSO-d6) d: 1.78 (s, 1H, NeCHeC), 2.62 (s, 1H,
CeCHeCl), 7.08e7.36 (m, 4H, ArH), 7.44e7.78 (m,4H,
ArH), and 10.21 (s, 1H, CONH); MS (m/z): Mþ calculated
385.99; found: 386.04.
2.3.2. N-{5-[(3-chloro-2-oxo-4-pyridin-4-ylazetidine1-yl)
sulfonyl]-1,3,4-thiadiazol-2-yl}acetamide (5b)
Colorless amorphous solid; MP: 236e239C; yield: 76%;
IR (KBr, cm1): 3292 (NeH), 3110 (ArCeH), 1672 (C]O,
amide), 1584 (ArC]C), 1368 (CeN), and 692 (CeCl); 1H-
NMR (DMSO-d6) d: 1.92 (s, 1H, NeCHeC), 2.42 (s, 1H,
CeCHeCl), 7.21e7.38 (m, 4H, ArH), 7.42-7.68 (m,4H,
ArH), and 10.34 (s, 1H, CONH); MS (m/z): Mþ calculated
386.98; found: 387.06.
2.3.3. N-(5-{[3-chloro-2-(4-fluorophenyl)-4-oxoazetidin-1-
yl]sulfonyl}-1,3,4-thiadiazol-2-yl)acetamide (5c)
Colorless amorphous solid; MP: 266e268C; yield: 81%; IR
(KBr, cm1): 3286 (NeH), 3162 (ArCeH), 1720 (C]O,
amide), 1565 (ArC]C), 1472 (CeN), and 708 (CeCl); 1H-
NMR (DMSO-d6) d: 1.87 (d, 1H, N-CH-C), 2.56 (d, 1H, C-CH-
Cl), 7.10 (m, 4H, ArH), 7.45 (m, 4H, ArH), and 10.12 (s, 1H,
CONH); MS (m/z): Mþ calculated 403.98.05; found: 404.04.
2.3.4. N-(5-{[3-chloro-2-(3-fluorophenyl)-4-oxoazetidin-1-
yl]sulfonyl}-1,3,4-thiadiazol-2-yl)acetamide (5d)
Colorless amorphous solid; MP: 254e257C; yield: 79%;
IR (KBr, cm1): 3314 (NeH), 3084 (ArCeH), 1672 (C]O,
amide), 1448 (ArC]C), 1392 (CeN), and 694 (CeCl); 1H-
NMR (DMSO-d6) d: 1.95 (s, 1H, N-CH-C), 2.38 (s, 1H, C-
CH-Cl), 7.08e7.36 (m, 4H, ArH), 7.23e7.58 (m,4H, ArH),
and 10.14 (s, 1H, CONH); MS (m/z): Mþ calculated 403.98;
found: 404.04.
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yl]sulfonyl}-1,3,4-thiadiazol-2-yl)acetamide (5e)
Colorless amorphous solid; MP: 248e251C; yield-77%;
IR (KBr, cm1): 3310 (NeH), 3082 (ArCeH), 1748 (C]O,
amide), 1564 (ArC]C), 1378 (CeN), and 704 (CeCl); 1H-
NMR (DMSO-d6) d: 1.88 (s, 1H, N-CH-C), 2.74 (s, 1H, C-
CH-Cl), 7.08e7.38 (m, 4H, ArH), 7.42e7.78 (m,4H, ArH),
and 10.34 (s, 1H, CONH); MS (m/z): Mþ calculated 419.95;
found: 420.04.
2.3.6. N-(5-{[3-chloro-2-(3-chlorophenyl)-4-oxoazetidin-1-
yl]sulfonyl}-1,3,4-thiadiazol-2-yl)acetamide (5f)
Colorless amorphous solid; M.P: 228e231C; yield: 63%; IR
(KBr, cm1): 3366 (NeH), 3068 (ArCeH), 1664 (C]O, amide),
1478 (ArC]C), 1392 (CeN), and 704 (CeCl); 1H-NMR
(DMSO-d6) d: 2.04 (s, 1H, N-CH-C), 2.68 (s, 1H, C-CH-Cl),
7.16e7.37 (m, 4H, ArH), 7.48e7.84 (m,4H, ArH), and 10.23 (s,
1H, CONH); MS (m/z): Mþ calculated 419.95; found: 420.02.
2.3.7. N-(5-{[3-chloro-2-(3-nitrophenyl)-4-oxoazetidin-1-
yl]sulfonyl}-1,3,4-thiadiazol-2-yl)acetamide (5g)
Colorless amorphous solid; MP: 246e249C; yield: 76%;
IR (KBr, cm1): 3287 (NeH), 3182 (ArCeH), 1726 (C]O,
amide), 1494 (ArC]C), 1376 (CeN), and 702 (CeCl); 1H-
NMR (DMSO-d6) d: 1.92 (s, 1H, N-CH-C), 2.85 (s, 1H, C-
CH-Cl), 7.12e7.34 (m, 4H, ArH), 7.41e7.82 (m, 4H, ArH),
and 10.23 (s, 1H, CONH); MS (m/z): Mþ calculated 430.97;
found: 431.03.
2.3.8. N-(5-{[3-chloro-2-(2-nitrophenyl)-4-oxoazetidin-1-
yl]sulfonyl}-1,3,4-thiadiazol-2-yl)acetamide (5h)
Colorless amorphous solid; MP: 278e281C; yield: 68%; IR
(KBr, cm1): 3292 (NeH), 3075 (ArCeH), 1726 (C]O, amide),
1492 (ArC]C), 1334 (CeN), and 703 (CeCl); 1H-NMR
(DMSO-d6) d: 1.97 (s, 1H, N-CH-C), 2.64 (s, 1H, C-CH-Cl),
7.06e7.38 (m, 4H, ArH), 7.42e7.78 (m, 4H, ArH), and 10.28 (s,
1H, CONH); MS (m/z): Mþ calculated 430.97; found: 431.04.
2.3.9. N-(5-{[3-chloro-2-(2-chlorophenyl)-4-oxoazetidin-1-
yl]sulfonyl}-1,3,4-thiadiazol-2-yl)acetamide (5i)
Colorless amorphous solid; MP: 292e295C; yield: 80%;
IR (KBr, cm1): 3268 (NeH), 3047 (ArCeH), 1672 (C]O,
amide), 1487 (ArC]C), 1356 (CeN), and 704 (CeCl); 1H-
NMR (DMSO-d6) d: 1.96 (d, 1H, NeCHeC), 2.62 (d, 1H,
CeCHeCl), 7.21e7.39 (m, 4H, ArH), 7.43e7.81 (m, 4H,
ArH), and 10.16 (s, 1H, CONH); MS (m/z): Mþ calculated
419.95; found: 420.01.
2.3.10. N-{5-[(3-chloro-2-oxo-4-pyridin-3-ylazetidin-1-yl)
sulfonyl]-1,3,4-thiadiazol-2-yl}acetamide (5j)
Colorless amorphous solid; MP: 226e228C; yield: 53%;
IR (KBr, cm1): 3254 (NeH), 3075 (ArCeH), 1716 (C]O,
amide), 1463 (ArC]C), 1376 (CeN), and 703 (CeCl); 1H-
NMR (DMSO-d6) d: 1.94 (s, 1H, NeCHeC), 2.46 (s, 1H,
CeCHeCl), 7.13e7.38 (m, 4H, ArH), 7.40e7.72 (m, 4H,
ArH), and 10.09 (s, 1H, CONH); MS (m/z): Mþ calculated
387.82; found: 387.87.2.3.11. N-(5-{[3-chloro-2-(furan-2-yl)-4-oxoazetidin-1-yl]
sulfonyl}-1,3,4-thiadiazol-2-yl)acetamide (5k)
Colorless amorphous solid; MP: 254e257C; yield: 64%; IR
(KBr, cm1): 3263 (NeH), 3045 (ArCeH), 1714 (C]O, amide),
1458 (ArC]C), 1366 (CeN), and 696 (CeCl); 1H-NMR
(DMSO-d6) d: 1.91 (s, 1H, NeCHeC), 2.52 (s, 1H, CeCHeCl),
7.21e7.41 (m, 4H, ArH), 7.45e7.78 (m, 4H, ArH), and 10.16 (s,
1H, CONH); MS (m/z): Mþ calculated 375.92; found: 375.86.2.4. AChE inhibitory activity
2.4.1. In vitro inhibition studies on AChE and
butylcholinesterase
AChE (from electric eel), butylcholinesterase (BuChE,
from equine serum), 5,50-dithiobis-(2-nitrobenzoic acid), ace-
tylthiocholine chloride, butylthiocholine chloride, and hydro-
chloride were purchased from Sigma-Aldrich. Indolizine
derivatives were dissolved in DMSO and diluted in 0.1M
KH2PO4/K2HPO4 buffer (pH 8.0) to provide a final concen-
tration range. DMSO was diluted to a concentration in excess
of 1 in 10,000, and no inhibitory action on either AChE or
BuChE was detected in separate prior experiments.
2.4.2. In vitro AChE assay
All the assays were carried out under 0.1M KH2PO4/
K2HPO4 buffers, pH 8.0, using a Shimadzu UV-2450 Spec-
trophotometer. Enzyme solutions were prepared to give
2.0 units/mL in 2 mL aliquots. The assay medium (1 mL)
consisted of phosphate buffer (pH 8.0), 50 mL of 0.01M 5,50-
dithiobis-(2-nitrobenzoic acid), 10 mL of enzyme, and 50 mL
of 0.01 M substrate (acetylthiocholine chloride solution). Test
compounds were added to the assay solution and preincubated
at 37C with the enzyme for 15 minutes followed by the
addition of substrate. The activity was determined by
measuring the increase in absorbance at 412 nm at 1
minute intervals at 37C. Calculations were performed ac-
cording to the method of the equation in Ellman method.21
Each concentration was assayed in triplicate. In vitro BuChE
assay was similar to the method used for AChE.
2.4.3. In vitro cytotoxicity
A short-term in vitro cytotoxicity assay was performed
using Vero cells, according to the standard procedure.22 Sul-
forhodamine B (SRB) is a bright-pink aminoxanthene dye
with two sulfonic groups. Under mild acidic conditions, SRB
binds to protein basic amino acid residues in trichloroacetic
acid-fixed cells to provide a sensitive index of cellular protein
content that is linear over a cell density range of at least two
orders of magnitude. After incubation, the solutions in the
wells were flicked off and 100 mL of different concentrations
(2e500 mg) of compounds were added to the cells and incu-
bated at 37C for 3 days in 5% CO2 atmosphere. The micro-
scopic examinations were performed and observations were
recorded every 24 hours. After, 72 hours, 50% trichloroacetic
acid (25 mL) was added to each well and the plates were
incubated for 1 hour at 4C. The supernatant was then
removed, and the cells were washed with water, air-dried, and
23K. Elumalai et al. / Journal of Acute Medicine 4 (2014) 20e25each well stained with SRB for 30 minutes. The unbound dye
was removed by washing with 1% acetic acid and the plates
were air dried. Tris base (10mM, 100 mL) was added to wells
to solubilize the dye. The plates were vigorously shaken for 5
minutes, and the absorbance was measured using a Microtiter
plate reader at 540 nm. The mean absorbance of triplicate was
recorded. Mean observance taken from cells grown in the
absence of the test compound was taken as 100% cell survivalGrowth inhibition %¼ 100 ½sample absorbance=control absorbance  100 ½1(control). The percentage growth inhibition was calculated
using the following formula:
3. Results
A series of 11 novel acetazolamide-condensed azetidinone
derivatives of biological interest were synthesized and evalu-
ated for AChE inhibitory activity and in vitro cytotoxicity; all
the compounds were purified and analyzed by IR, 1H-NMR,
and MS for their structure.3.1. ChemistrySynthesis of azetidinone derivatives by adopting conden-
sation reaction was performed by following the steps as out-
lined in Fig. 1. In the first step synthesis of Schiff’s base of
acetazolamide reacted with chloroacetyl chloride in the
presence of triethyl amine and 1,4-dioxane under neat con-
ditions resulting in the formation of the product. The reaction
times were found to be 4.5 hours. In total, 11 compoundsa
S
N N
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O
NH2NH
CH3
O
RCHO
CH3
1
Fig. 1. Reagents and conditions: (a) 95% ethanol, reflux 3.5 hours; ((5aek), various substituted azetidinone derivatives, were
synthesized with the yield ranging from 53% to 81%. These
conditions enable this method to be applicable for the syn-
thesis of azetidinone-based heterocyclic compounds. The
azetidinones were synthesized relatively easily by using
triethyl amine and 1,4-dioxane as an efficient catalyst. The
present protocol best describes the synthesis of azetidinone
derivative compounds, which were found to be novel and notreported elsewhere.3.2. AChE inhibitory activityAmong the novel substituted azetidinone derivatives for
treating AD, their anticholinesterase activities (compounds
5aek) was assayed according to Ellmann’s method on
AChE from electric eel using commercial donepezil HCl as
the reference standard. The inhibitory effects on equine
serum BuChE were also examined by the same method.
Inhibition of AChE by the synthesized compounds is shown
in Table 1. The data listed in Table 1 clearly show that most
of the designed compounds exhibited good to moderate
inhibitory activities toward the AChE and BuChE inhibition.
All azetidinone derivatives were potent inhibitors of AChE,
with IC50 values ranging from micromolar to sub-
micromolar. Compound 5c showed the best AChE and
BuChE inhibitory activity of all the azetidinone derivatives,
with 0.10mM and 3.4mM, respectively, leading to 50%
inhibition.b
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b) triethyl amine, 1,4-dioxane, stir 20 minutes, reflux 4.5 hours.
Table 1
Synthesized azetidinones: in vitro acetylcholinesterase inhibitor and cytotoxic assay.
S. no Compound R AChE IC50
(m)  SEM
BuChE IC50
(mM)  SEM
CTC50 (mg/mL)
on Vero cells
1 5a phenyl 8.7  0.01 9.4  0.02 78.75
2 5b 4-pyridyl 1.5  0.01 5.7  0.01 29.50
3 5c 4-flurophenyl 0.11  0.1 3.4  0.1 12
4 5d 3-flurophenyl 0.82  0.01 4.3  0.01 22
5 5e 4-chlorophenyl 0.36  0.1 4.1  0.01 18.50
6 5f 3-chlorophenyl 1.2  0.01 6.8  0.02 38
7 5g 3-nitrophenyl 2.6  0.01 6.7  0.01 44
8 5h 2-nitrophenyl 4.4  0.01 9.2  0.01 68
9 5i 2-chlorophenyl 3.1  0.1 9.6  0.01 70
10 5j 3-pyridyl 2.8  0.01 6.3  0.01 74
11 5k 2-furyl 5.1  0.1 7.8  0.01 110
12 Donepezil HCl Standard 0.14  0.01 3.5  0.01 -
AChE ¼ acetylcholinesterase; BChE ¼ butylcholinesterase; CTC50 ¼ concentration of the sample required to kill 50% of the cells; R ¼ substituted aryl
group S. ¼ sample number.
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cytotoxicity assay against Vero cells. The assay was performed
by the SRB method.22 Almost all of the named compounds
exhibited weak, moderate, or high cytotoxicity. Compound, 5c
exhibited significant cytotoxic activity with the lowest con-
centration required to kill 50% of the cells (Table 1).4. Discussion
Analyzing the activities of the synthesized compounds, the
following structure activity relationships were obtained. The
N1 position of azetidinone derivatives contains acetazolamide
groups that contribute toward activity against AChE, BChE,
and in vitro cytotoxicity against Vero cells. The second posi-
tion of the azetidinone contains heteroaryl and the substituted
aryl group showed more potent acetylcholine esterase inhibi-
tory activity and in vitro cytotoxicity (Table1). Among the
reported compounds, compound 5c contains a 4-fluro
substituted phenyl group at the second position of azetidi-
none showed potent AChE inhibitory activity and in vitro
cytotoxicity when compared with chloro, nitro, and heteroaryl
group substituted azetidinones due to the strong electron
withdrawing nature of the fluorine atom because it decreases
the electron density in the ring. The order of reactivity of the
titled compound contains substituted phenyl ring at the second
position of azetidinone is F > Cl > NO2. The unsubstituted
phenyl group (5a) showed lesser AChE inhibition and in vitro
cytotoxicity, when compared with the other compounds.
In conclusion, a series of novel acetazolamide-condensed
azetidinones of biological interest was synthesized and their
structures analyzed. The azetidinones were prepared by using
triethylamine in 1,4-dioxane as an efficient catalyst. The
importance of substitutions at the second positions of azeti-
dinones was studied toward the AChE inhibitory activity and
in vitro cytotoxicity. Almost all of the titled compounds
exhibited weak, moderate, or high AChE inhibitory activity
and in vitro cytotoxicity. Of the compounds reported herein,compound 5c is arguably the most potent and this study sug-
gests that it is an interesting compound when compared to the
current therapeutic agent donepezil HCl and should be
considered as a candidate for further investigation.
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